These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 29210919

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J, Grancher K, Mandel F, Daum F.
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [Abstract] [Full Text] [Related]

  • 3. Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.
    Barfield E, Sockolow R, Hoffenberg E, Saeed S, Kim S, Siebold L, Picoraro J, Moses J, Dykes D, Grossman A, Wahbeh G, Park KT.
    J Pediatr Gastroenterol Nutr; 2018 Apr; 66(4):680-686. PubMed ID: 29324477
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?
    Ward MG, Irving PM, Sparrow MP.
    World J Gastroenterol; 2015 Oct 28; 21(40):11331-42. PubMed ID: 26525434
    [Abstract] [Full Text] [Related]

  • 6. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
    Hirten RP, Iacucci M, Shah S, Ghosh S, Colombel JF.
    Clin Gastroenterol Hepatol; 2018 Sep 28; 16(9):1374-1384. PubMed ID: 29481970
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.
    Qiu Y, Mao R, Chen BL, Zhang SH, Guo J, He Y, Zeng ZR, Ben-Horin S, Chen MH.
    Clin Gastroenterol Hepatol; 2017 Sep 28; 15(9):1359-1372.e6. PubMed ID: 28232073
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition.
    Kleinman RE, Baldassano RN, Caplan A, Griffiths AM, Heyman MB, Issenman RM, Lake AM, Motil KJ, Seidman E, Udall JN, North American Society for Pediatric Gastroenterology, Hepatology And Nutrition.
    J Pediatr Gastroenterol Nutr; 2004 Jul 28; 39(1):15-27. PubMed ID: 15187775
    [Abstract] [Full Text] [Related]

  • 11. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA.
    Clin Gastroenterol Hepatol; 2015 Dec 28; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [Abstract] [Full Text] [Related]

  • 12. Use of biologic agents in pediatric inflammatory bowel disease.
    Rosh JR.
    Curr Opin Pediatr; 2009 Oct 28; 21(5):646-50. PubMed ID: 19629010
    [Abstract] [Full Text] [Related]

  • 13. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.
    Johnson CM, Dassopoulos T.
    Curr Gastroenterol Rep; 2018 Sep 28; 20(11):53. PubMed ID: 30267281
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.
    Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S.
    Clin Gastroenterol Hepatol; 2014 Sep 28; 12(9):1474-81.e2; quiz e91. PubMed ID: 24486408
    [Abstract] [Full Text] [Related]

  • 17. Use of biological molecules in the treatment of inflammatory bowel disease.
    Nielsen OH, Seidelin JB, Munck LK, Rogler G.
    J Intern Med; 2011 Jul 28; 270(1):15-28. PubMed ID: 21241384
    [Abstract] [Full Text] [Related]

  • 18. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB.
    Gut; 2007 Sep 28; 56(9):1181-3. PubMed ID: 17698862
    [Abstract] [Full Text] [Related]

  • 19. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L.
    Minerva Gastroenterol Dietol; 2010 Jun 28; 56(2):233-43. PubMed ID: 20485259
    [Abstract] [Full Text] [Related]

  • 20. Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All.
    Melmed GY, Kaplan GG, Sparrow MP, Velayos FS, Baidoo L, Bressler B, Cheifetz AS, Devlin SM, Irving PM, Jones J, Kozuch PL, Raffals LE, Siegel CA.
    Clin Gastroenterol Hepatol; 2018 Nov 28; 16(11):1829-1831. PubMed ID: 29505910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.